Latest ROE for XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th: 27.91% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow27.91%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's return on equity stands at 27.91%. That is above the Healthcare sector average of 21.67%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th sits higher the Healthcare benchmark (21.67%) with a ROE of 27.91%. That is roughly 28.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 27.91% for XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's ROE evolved across reporting periods, while the comparison chart places XOMAO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's reading of 27.91% (sector avg 21.67%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.